These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33888985)

  • 1. Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia.
    Ohnishi T; Wakamatsu A; Kobayashi H
    Neuropsychiatr Dis Treat; 2021; 17():1095-1104. PubMed ID: 33888985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
    Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
    BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 5. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
    Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
    BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
    Kim S; Kim S; Koh M; Choi G; Kim JJ; Paik IH; Kim SH; Choi YS; Lee Y; Suh J; Takeuchi H; Uchida H; Kim E
    J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Symptomatic remission and its relationship to social functioning in Tunisian out-patients with schizophrenia].
    El Gharbi I; Chhoumi M; Mechri A
    Encephale; 2019 Feb; 45(1):15-21. PubMed ID: 29195805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
    Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ
    Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
    Nash AI; Turkoz I; Savitz AJ; Mathews M; Kim E
    Neuropsychiatr Dis Treat; 2019; 15():731-737. PubMed ID: 30962688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.
    Li N; Feng Y; Lu H; Cai SL; Zhuo J; Si T; Zhang L
    Neuropsychiatr Dis Treat; 2018; 14():825-837. PubMed ID: 29606876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study.
    Li Y; Zhang L; Zhang Y; Wen H; Huang J; Shen Y; Li H
    Neuropsychiatr Dis Treat; 2021; 17():847-857. PubMed ID: 33776440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
    Leucht S; Zhao J
    J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year functional outcomes of naturalistically treated patients with schizophrenia.
    Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
    Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission.
    Gorwood P; Bouju S; Deal C; Gary C; Delva C; Lancrenon S; Llorca PM
    Psychiatry Res; 2019 Nov; 281():112560. PubMed ID: 31521843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
    Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
    Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.